AbbVie has forged a partnership worth up to $2.5bn with German biotech Disco Pharmaceuticals focused on bispecific cancer therapies for solid tumours.  

Through this agreement, AbbVie will hand over $40m upfront, while committing up to $2.5bn in option, development and other milestones and tiered royalties on potential global net sales to work with Disco. The Illinois-based pharma giant will also secure the option to exclusively license selected therapies from this partnership for further development, provided Disco successfully completes certain research activities. 

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The pair will collaborate on the discovery and development of selective bispecifics, which Disco will design to address solid tumour indications with high unmet needs. Neither company has yet divulged which indications they plan to pursue through this collaboration. 

At the heart of Disco’s approach is the DISCOtech platform, which the company uses to design novel AND-gated antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). According to the biotech, AND-gated therapeutics could hold promise in broadening the range of addressable targets for bispecific therapies, while diminishing the presence of on-target, off-tumour toxicity. 

According to Disco’s CEO, Mark Manfredi, DISCOtech’s ability to identify tumour-selective target pairs is unique to the field, and “provides the foundation for therapies with the potential for a wider therapeutic window.” 

AbbVie’s deal with Disco follows on from several high-profile deals the company has forged in recent months – including its $1.38bn inflammatory bowel disease (IBD)-focused agreement with Nxera, as well as its $10.9bn takeover of Apogee Therapeutics. 

Targeted modalities take centre stage in solid tumour space 

While chemotherapy has long been considered a workhorse in the solid tumour treatment paradigm, experts say that drugs with targeted mechanisms, such as ADCs, TCEs and bispecific antibodies, are beginning to displace chemo as the frontline treatment backbone across certain indications. 

With this trend playing out in real-time, many pharma companies are looking to develop drugs that hold promise across a broad range of solid tumour indications. 

The the space is currently exploring several targets, many companies are learning towards checkpoint inhibitor bispecifics, including Pfizer, MSD (Merck & Co) and BioNTech & Bristol Myers Squibb (BMS), which are hedging their bets on PD-1 or PD-L1 and VEGF-targeting drugs.  

Some are also evaluating the promise of drugs targeting PD-1 and CTLA-4, with AstraZeneca and Akeso both currently progressing their respective drugs, volrustomig and cadonilimab, through clinical trials across a broad range of indications. 

According to a report from GlobalData, the parent company of Pharmaceutical Technology, the total immuno-oncology market, including bispecific antibodies, cancer vaccines, checkpoint modulators, cell therapies, cytokines, and oncolytic viruses, will reach a value of $186bn by 2031.